Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales SlowInvestors Business Daily • 01/14/25
Lilly's Zepbound and Mounjaro Sales Miss Estimates Again. The Wobble's Looking Serious.Barrons • 01/14/25
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock TanksBenzinga • 01/14/25
Lilly asks US government to pause drug price negotiation program, Bloomberg News reportsReuters • 01/13/25
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor programPRNewsWire • 01/13/25
High-cost weight loss drugs are sending employers to nutrition counseling in a boost for startupsCNBC • 01/10/25
Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Venture FundBusiness Wire • 01/10/25
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?Zacks Investment Research • 01/10/25
Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli LillyMarket Watch • 01/09/25